AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2021 Earnings Conference Call March 30, 2021 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Matt Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2021 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-a ...

业绩总结 - AngioDynamics 2021年上半年公司收入为1.43亿美元，同比增长5.1%[51] - 2021年上半年公司调整后每股收益为0.03美元，同比下降0.11美元[51] - 2021年上半年公司调整后息税折旧摊销前利润（EBITDA）为960万美元，同比下降4.1百万美元[51] - 2021年第二季度公司现金为5800万美元，较2020年第四季度增长3.6百万美元[52] - 2021财年公司预计收入在2.78亿至2.84亿美元之间[53] 用户数据 - 2020年美国新诊断的癌症病例为1,256,970例，其中18%为肺癌，15%为乳腺癌，12%为前列腺癌[41] - 2020年美国前列腺癌患者中，31%将接受根治性前列腺切除术，79%在36个月后报告勃起功能障碍[46] - 2020年美国前列腺癌患者中，38%被认为是局部治疗的理想候选者[46] 新产品和技术研发 - AngioDynamics的NanoKnife系统已获得FDA的510(k)批准，用于软组织的外科消融[3] - AngioDynamics计划在2021年推出Auryon系统，进入外周动脉切除市场[9] - NanoKnife系统的独特技术能够在以前无法到达的部位提供局部治疗[40] - AngioDynamics的多功能机械吸引装置预计将扩展到DVT和PE的可寻址市场，提供无需灌注的首选治疗选项[34] - AngioDynamics的计划产品组合扩展包括针对肺栓塞的指示，预计将增加1.3亿美元的市场机会[37] 市场扩张和并购 - AngioDynamics的深静脉血栓形成（DVT）和肺栓塞（PE）市场分别有208,000和171,000个高风险病例[27] - AngioDynamics的AngioVac系统在右心的可寻址市场为7700万美元[32] - AngioDynamics的战略转型依赖于研发、并购和临床及监管路径的扩展，以在快速增长的市场中占据一席之地[14] 负面信息 - NanoKnife系统的潜在不良反应包括心律失常和心房颤动[60] 其他新策略和有价值的信息 - AngioDynamics的产品开发管道将持续扩展，关注客户反馈和市场需求[25] - AngioDynamics的非GAAP财务指标包括调整后的EBITDA和自由现金流，帮助投资者分析业务趋势[4]

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2021 Earnings Conference Call January 7, 2021 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Matthew Mishan - KeyBanc Capital Markets Bill Plovanic - Canaccord Genuity Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2021 Second Quarter Earnings Call. At this time, all participants ar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3146460 (State or other juris ...